Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5349497 | 0.84 | HDAC6 (0.36) | HDAC6KDM4EALDH1A1GLAGAA | |
| SCHEMBL4436717 | 0.84 | HSD17B10 (0.33) | HDAC6KDM4EALDH1A1GLAGAA | |
| SCHEMBL31269349 | 0.84 | HSD17B10 (0.33) | HDAC6KDM4EALDH1A1GLAGAA | |
| SCHEMBL7771667 | 0.82 | SLC2A1 (0.37) | HDAC6KDM4EALDH1A1GLAGAA | |
| SCHEMBL1721310 | 0.82 | GDA (0.39) | HDAC6KDM4EALDH1A1GLAGAA | |
| SCHEMBL6046332 | 0.79 | KDM4E (0.31) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL19207482 | 0.78 | — | — | |
| SCHEMBL6060475 | 0.78 | CTNNB1 (0.30) | — | |
| SCHEMBL4520172 | 0.71 | ALDH1A1 (0.50) | KDM4EALDH1A1 | |
| SCHEMBL2009845 | 0.71 | KDM4E (0.35) | KDM4EALDH1A1GLAGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | DEVGEN NV (BE) | 2009-09-17 | — | — | US | disclosed |
| EP-1934181-A2 | KINASE INHIBITORS | Devgen NV (BE) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007042321-A2 | KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233960-A1 | Kinase Inhibitors | ROCK1, MAP3K1, MAP3K11 | HDAC6 1082/4885KDM4E 4294/4885ALDH1A1 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.